Comparative Pharmacology
Head-to-head clinical analysis: FINTEPLA versus MILONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINTEPLA versus MILONTIN.
FINTEPLA vs MILONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.
Increases seizure threshold by inhibiting voltage-gated sodium channels and enhancing GABAergic inhibition.
0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.
Oral, 500 mg twice daily; may increase by 250-500 mg/day every 2-3 days; usual dose 1-2 g/day in 2-3 divided doses; maximum 3 g/day.
None Documented
None Documented
Terminal elimination half-life approximately 9 hours in adults; at steady state, accumulation minimal with twice-daily dosing.
Terminal elimination half-life is 6–8 hours in adults, longer in children (8–12 hours) and elderly (10–14 hours); clinical context: requires multiple daily dosing to maintain therapeutic levels.
Renal: 65% as unchanged drug; Fecal: 29% primarily as metabolites; Biliary: negligible.
Primarily hepatic metabolism and renal excretion; approximately 60% of a dose is excreted in urine as conjugated metabolite (phensuximide glucuronide), with 15% as unchanged drug; 20% eliminated in feces.
Category C
Category C
Antiepileptic
Antiepileptic